• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A Pilot Randomized Controlled Trial Evaluating Hemostasis With Fibrin Glue During Surgery for Proliferative Diabetic Retinopathy.

作者信息

Takkar Brijesh, Ketkar Manasi Raj, Narula Ritesh, Tyagi Mudit, Dave Vivek Pravin, Narayanan Raja

机构信息

From the Indian Health Outcomes, Public Health, and Economics Research Center (B.T., Ra.N.); the Anant Bajaj Retina Institute (B.T., M.R.K., Ri.N., M.T., V.P.D., Ra.N.), LV Prasad Eye Institute, Hyderabad, Telangana, India..

the Anant Bajaj Retina Institute (B.T., M.R.K., Ri.N., M.T., V.P.D., Ra.N.), LV Prasad Eye Institute, Hyderabad, Telangana, India.

出版信息

Am J Ophthalmol. 2025 Apr;272:117-125. doi: 10.1016/j.ajo.2025.01.016. Epub 2025 Jan 28.

DOI:10.1016/j.ajo.2025.01.016
PMID:39884371
Abstract

PURPOSE

To evaluate the safety and efficacy of fibrin glue in preventing early recurrence of vitreous hemorrhage following surgery for proliferative diabetic retinopathy (PDR).

DESIGN

Single-masked randomized controlled clinical trial.

SUBJECTS

Consecutive patients with vitreous hemorrhage due to PDR undergoing primary vitreoretinal surgery were screened. After completing all vitreoretinal maneuvers including endocautery to bleeders, infusion pressure was gradually reduced to 5 mm Hg. Eyes with persistent bleeders at the macula and/or the optic nerve head not amenable to endocautery were included. Eyes with tractional retinal detachment more than 5-disc-diameter areas and/or retinal breaks were excluded.

METHODS

Twenty eyes were randomized into 2 groups. Controls were treated with conventional surgery, whereas cases were additionally treated with fibrin glue application over the posterior bleeding sites.

MAIN OUTCOME MEASURES

Vitreous haze due to early recurrent vitreous hemorrhage was graded at weeks 1 and 4 as the main efficacy outcome measure. Absence of macular membranes at 3 months was the main safety outcome measure.

RESULTS

Mean age, frequency of preoperative anti-vascular endothelial growth factor injection or retinal photocoagulation, antiplatelet usage, and mean intraoperative blood pressures were similar between the 2 groups. Mean surgery duration (54.6 vs 51.6 minutes) and frequency of fibrous proliferation >2-disc-diameter areas (7 each) was similar. Fine dissection with forceps and/or scissors was required in more cases than controls (6 vs 3). Macular membranes were noted in 1 participant in each group. Mean grade of vitreous haze was significantly higher in controls than cases at week 1 (2.4 vs 0.6, P = .027) and week 4 (2 vs 0, P = .029). Cases had significantly better odds of having optically clear vitreous cavity at both week 1 (odds ratio [OR] 8.167, CI 1.02-64.03; P = .047) and week 4 (OR 33, CI 1.43-760.67; P = .029). Repeat retinal intervention for vitreous hemorrhage within 3 months was required in 5 of 10 controls, and in none of the cases.

CONCLUSION

Our findings indicate fibrin glue application under direct visualization to be safe and efficacious in preventing recurrent vitreous hemorrhage for PDR in the early postoperative period.

摘要

相似文献

1
A Pilot Randomized Controlled Trial Evaluating Hemostasis With Fibrin Glue During Surgery for Proliferative Diabetic Retinopathy.
Am J Ophthalmol. 2025 Apr;272:117-125. doi: 10.1016/j.ajo.2025.01.016. Epub 2025 Jan 28.
2
Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis.抗血管内皮生长因子药物与激光光凝术治疗增殖性糖尿病视网膜病变的比较:一项系统评价和个体参与者数据荟萃分析
Health Technol Assess. 2025 Apr 2:1-75. doi: 10.3310/MJYP6578.
3
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis.抗血管内皮生长因子药物与激光光凝术治疗糖尿病性视网膜病变的比较:一项系统评价和荟萃分析。
Health Technol Assess. 2024 Dec 11:1-71. doi: 10.3310/PCGV5709.
4
Laser therapy for retinopathy in sickle cell disease.激光疗法治疗镰状细胞病视网膜病变。
Cochrane Database Syst Rev. 2022 Dec 12;12(12):CD010790. doi: 10.1002/14651858.CD010790.pub3.
5
Ocriplasmin for symptomatic vitreomacular adhesion.用于有症状性玻璃体黄斑粘连的奥克纤溶酶
Cochrane Database Syst Rev. 2017 Oct 17;10(10):CD011874. doi: 10.1002/14651858.CD011874.pub2.
6
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.抗血管内皮生长因子治疗糖尿病性黄斑水肿:一项网状Meta分析。
Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5.
7
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.抗血管内皮生长因子治疗增生型糖尿病视网膜病变。
Cochrane Database Syst Rev. 2023 Mar 20;3(3):CD008721. doi: 10.1002/14651858.CD008721.pub3.
8
Different lasers and techniques for proliferative diabetic retinopathy.用于增殖性糖尿病视网膜病变的不同激光和技术。
Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD012314. doi: 10.1002/14651858.CD012314.pub2.
9
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.抗血管内皮生长因子联合玻璃体内注射类固醇治疗糖尿病性黄斑水肿。
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD011599. doi: 10.1002/14651858.CD011599.pub2.
10
Anti-vascular endothelial growth factor for neovascular glaucoma.抗血管内皮生长因子治疗新生血管性青光眼。
Cochrane Database Syst Rev. 2023 Apr 3;4(4):CD007920. doi: 10.1002/14651858.CD007920.pub4.